

Curriculum Vitae

Personal information **John Aspegren**

Work experience

1. Employer: Finnish Medicines Agency Fimea
 - Start date: 082022
 - End date:
 - Position: Biostatistician
 - Activities:
 - Country: Finland
2. Employer: Orion Corporation
 - Start date: 042002
 - End date: 052022
 - Position: Senior Biostatistician
 - Activities: Started in 2002 as Study Statistician in CNS and Animal Health projects. Later worked as both Project Statistician and Study Statistician in various therapy areas (human: oncology and CNS; Animal Health: pain, sedation, anxiety, and hypertension). From 2012 my title was Senior Biostatistician. Over the years, I have been involved in projects from earliest clinical phase all the way to applications for marketing approval. My work has included: _ participating in writing the Clinical Study Protocol and Clinical Study Report _ writing the SAP and SAR _ planning, analysing, and reporting of clinical studies _ using advanced statistical methodologies in analyses _ participating in DSMBs/DMCs _ using simulations and visualisations to aid decision making _ collaborating with FDA (CVM)/EMA
 - Country: Finland

Education and training

1. Subject: Åbo Akademi University
 - Start date: 081994
 - End date: 122002
 - Qualification: M.Sc. (statistics)
 - Organisation:
 - Country: Finland

Additional information

Publications

1. Granholm M, McKusick BC, Westerholm FC, Aspegren JC (08/2006). Evaluation of the clinical efficacy and safety of dexmedetomidine or medetomidine in cats and their reversal with atipamezole, Vet Anaesth Analg, 33(4), 214_223. <https://doi.org/10.1111/j.1467-2995.2005.00259.x>
2. M Granholm, B C McKusick, F C Westerholm, J C Aspegren (07/2007). Evaluation of the clinical efficacy and safety of intramuscular and intravenous doses of dexmedetomidine and medetomidine in dogs and their reversal with atipamezole, Vet Record, 160(26):891_7. <http://dx.doi.org/10.1136/vr.160.26.891>
3. Lin G_Y, Robben J, Murrell J, Aspegren J, McKusick BC & Hellebrekers L (01/2008). Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs, Vet Anaesth Analg, 35(2), 141_153. <https://doi.org/10.1111/j.1467-2995.2007.00365.x>
4. Valtolina C, Robben J, Uilenreef J, Murrell J, Aspegren J, McKusick BC, Hellebrekers L (06/2009). Clinical evaluation of the efficacy and safety of a constant rate infusion of dexmedetomidine for postoperative pain management in dogs, Vet Anaesth Analg, 36(4), 369_383. <https://doi.org/10.1111/j.1467-2995.2009.00461.x>
5. Kaukinen H, Aspegren J, Hyypä S, Tamm L, Salonen J. Bioavailability of detomidine administered sublingually to horses as an oromucosal gel. J Vet Pharmacol Ther <https://doi.org/10.1111/j.1365-2885.2010.01193.x>
6. Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M. Activity and safety of ODM_201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open_label phase 1 dose_escalation and randomised phase 2 dose expansion trial. Lancet Oncol, 08/2014; 15(9). [https://doi.org/10.1016/S1470-2045\(14\)70240-2](https://doi.org/10.1016/S1470-2045(14)70240-2)
7. M Huhtinen, G Derré, H J Renoldi, M Rinkinen, K Adler, J Aspegren, C Zemirline, J Elliott. Randomized Placebo-Controlled Clinical Trial of a Chewable Formulation of Amlodipine for the Treatment of Hypertension in Client-Owned Cats. J Vet Intern Med 04/2015. <https://doi.org/10.1111/jvim.12589>
8. Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, Wollmer P, Trägårdh E, Bondesson E, Edenbrandt L, Fizazi K, Bjartell A. Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM_201 in the ARADES Multicentre Study. Eur Urol Focus (2016), Available online 3 February 2016. <https://doi.org/10.1016/j.euf.2016.01.005>
9. Shore ND, Tammela T, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K. PD32_06 Long-term safety and antitumor activity of ODM_201 in chemotherapy and CYP17_inhibitor naïve patients from the ARADES and the ARAFOR trials. J Urol, Vol. 195, Issue 4, Supplement 2016. <https://dx.doi.org/10.1016/j.juro.2016.02.682>
10. Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela T, Joensuu H, Aspegren J, Mustonen M. Safety and Antitumour Activity of ODM_201 (BAY_1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer:

Results from Extended Follow-up of the ARADES Trial. Eur Urol Focus (2017), <http://dx.doi.org/10.1016/j.euf.2017.01.010>

11. Shore ND, Tammela T, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K. Safety and Antitumour Activity of ODM_201 (BAY_1841788) in Chemotherapy_naïve and CYP17 Inhibitor_naïve Patients: Follow-up from the ARADES and ARAFOR Trials. Eur Urol Focus (2017), <http://dx.doi.org/10.1016/j.euf.2017.01.015>

12. Ameratunga M, Braña I, Bono P, Postel_Vinay S, Plummer R, Aspegren J, Korjamo T, Snapir A, de Bono J. First_in_human Phase 1 open label study of the BET inhibitor ODM_207 in patients with selected solid tumours. Br J Cancer (2020). <https://doi.org/10.1038/s41416-020-01077-z>

13. Dai F, Rausk J, Aspegren J, Huhtinen M, Cannas S, Minero M. Use of Detomidine Oromucosal Gel for Alleviation of Acute Anxiety and Fear in Horses: A Pilot Study. Front. Vet. Sci. (2020). <https://doi.org/10.3389/fvets.2020.573309>

14. Korpivaara M, Huhtinen M, Aspegren J, Overall K. Dexmedetomidine oromucosal gel reduces fear and anxiety in dogs during veterinary visits: A randomised, double-blind, placebo-controlled clinical pilot study. Vet Rec. (2021). <http://doi.org/10.1002/vetr.832>

15. Lamminen T, Korpivaara M, Suokko M, Aspegren J, Palestini C, Overall K. Efficacy of a Single Dose of Pregabalin on Signs of Anxiety in Cats During Transportation—A Pilot Study. Front. Vet. Sci. (2021). <https://doi.org/10.3389/fvets.2021.711816>

16. Lehtimäki J, Jalava N, Unkila K, Aspegren J, Haapalinna A, Pesonen U. Tasipimidine—the pharmacological profile of a novel orally active selective α_2A adrenoceptor agonist. Eur. J. Pharmacol. (2022). <https://doi.org/10.1016/j.ejphar.2022.174949>

17. Singhal M, Turunen E, Ahtola_Setälä T, Aspegren J, Bratty JR, Fuhr R, Ojala K, vanVeen B, Peltonen L. Nanoparticle_based oral formulation can surprise you with inferior in vivo absorption in humans. Eur. J. Pharm. Biopharm. (2022). <https://doi.org/10.1016/j.ejpb.2022.06.009>

18. Lamminen T, Korpivaara M, Aspegren J, Palestini C, Overall K. Pregabalin alleviates anxiety and fear in cats during transportation and veterinary visits – a clinical field study. Animals (2023). <https://doi.org/10.3390/ani13030371>

19. Jones, R.H., Fizazi, K., James, N.D. *et al.* Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2023). <https://doi.org/10.1038/s41391-023-00740-9>

Projects

Memberships

Other Relevant Information